Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1

Journal of Interferon and Cytokine Research

Volumn 26, Issue 2, 2006, Pages 83-95

  Xiong, Yuning ^a   Donovan, Kathleen A ^a   Kline, Michael P ^a   Gornet, Michael K ^a   Moon Tasson, Laurie L ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a   Greipp, Philip R ^a   Lust, John A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROINTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; FEMALE; GENETIC TRANSDUCTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOLDERING MULTIPLE MYELOMA; STROMA CELL;

BONE MARROW CELLS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; STROMAL CELLS; SYNDECANS; TRANSDUCTION, GENETIC;

EID: 33644844811     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.83     Document Type: Article

References (55)

1. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Huntington) 2002;16:217-229.
2. Correa P. Helicobacter pylori as a pathogen and carcinogen. J. Physiol Pharmacol 1997;48(Suppl 4):19-24.
3. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950-954.
4. Hayashi PH, Zeldis JB. Molecular biology of viral hepatitis and hepatocellular carcinoma. Comprehens. Ther. 1993;19:188-196.
5. Pera M, Trastek VF, Pairolero PC, Cardesa A, Allen MS, Deschamps C. Barrett's disease: pathophysiology of metaplasia and adenocarcinoma. Ann. Thorac. Surg. 1993;56:1191-1197.
6. Miwa H, Kanno H, Munakata S, Akano Y, Taniwaki M, Aozasa K. Induction of chromosomal aberrations and growth-transformation of lymphoblastoid cell lines by inhibition of reactive oxygen species-induced apoptosis with interleukin-6. Lab. Invest. 2000;80:725-734.
7. Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol. Oncol. Clin. North Am. 1992;6:211-223.
8. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 1995;182:243-248.
9. Potter M, Wax JS. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J. Immunol. 1981;127:1591-1595.
10. Bataille R, Robinet-Levy M, Barchechath-Flaisler F, Peres S, Aznar R, Sany J. Immunofixation improves the detection of monoclonal gammopathy of undetermined significance (MGUS) in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 1987;5:259-261.
11. Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur. J. Cancer 1993;29A:259-263.
12. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J. Rheumatol. 1991;18:809-814.
13. Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinaemia in rheumatoid arthritis. Ann. Rheum. Dis. 1991;50:290-294.
14. Linet MS, McLaughlin JK, Harlow SD, Fraumeni JF. Family history of autoimmune disorders and cancer in multiple myeloma. Int. J. Epidemiol 1988;17:512-513.
15. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol 1990;74:424-431.
16. Donovan KA, Lacy MQ, Kline MP, Ahmann GJ, Heimbach JK, Kyle RA, Lust JA. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia 1998;12:593-600.
17. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999;93:300-305.
18. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. North Am. 1999;13:1117-1125.
19. Lust JA, Donovan KA, Greipp PR. Monoclonal gammopathies of undetermined significance: the transition from MGUS to myeloma. In: Gahrton G, Durie BGM, Samson DM, eds. Multiple Myeloma. Totowa, NJ: Humana Press; 2004:369-378.
20. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br. J. Haematol. 1998;103:1152-1160.
21. Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp. Hematol. 1996;24:868-874.
22. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 1986;137:245-254.
23. Terry RW, Kwee L, Levine JF, Labow MA. Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein. Proc. Natl. Acad. Sci. USA 1993;90:5919-5923.
24. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9:899-909.
25. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989;74:380-387.
26. Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J. Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res. 1989;49:4242-4246.
27. Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin. Hematol. 1989;26:176-200.
28. Lokhorst HM, Lamme T, de Smet M, Klein S, de Weger RA, van Oers R, Bloem AC. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994;84:2269-2277.
29. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
30. Kiss TL, Lipton JH, Bergsagel DE, Meharchand JM, Jamal N, Minden MD, Messner HA. Determination of IL6, IL1, and IL4 in the plasma of patients with multiple myeloma. Leuk. Lymphoma 1994;14:335-340.
31. Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haematol. 1993;85:446-451.
32. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-1112.
33. Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk. Lymphoma 1998;32:107-119.
34. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
35. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J Haematol. 2003;121:749-757.
36. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996;10:866-876.
37. Kruisbeek AM. Isolation and fractionation of mononuclear cell populations. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, eds. Current Protocols in Immunology: New York: John Wiley & Sons; 2000:3.1.3-3.1.5.
38. Kanof ME, Smith PD, Zola H. Preparation of human mononuclear cell populations and subpopulations. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, eds. Current Protocols in Immunology. New York: John Wiley & Sons; 1996:7.1.1-7.1.7.
39. Nishida T, Nishino N, Takano M, Kawai K, Bando K, Masui Y, Nakai S, Hirai Y. cDNA cloning of IL-1 alpha and IL-1 beta from mRNA of U937 cell line. Biochem. Biophys. Res. Commun. 1987;143:345-352.
40. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
41. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N. Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat. Med. 2003;9:47-52.
42. Auron PE, Webb AC. Interleukin-1: a gene expression system regulated at multiple levels. Eur. Cytokine New. 1994;5:573-592.
43. Lust JA. Role of cytokines in the pathogenesis of monoclonal gammopathies. Mayo Clin. Proc. 1994;69:691-697.
44. Greipp PR, Lust JA. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells 1995;13(Suppl 2):10-21.
45. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314-1325.
46. Luk WP, Zhang Y, White TD, Lue FA, Wu C, Jiang CG, Zhang L, Moldofsky H. Adenosine: a mediator of interleukin-1beta-induced hippocampal synaptic inhibition. J. Neurosci. 1999;19:4238-4244.
47. Orencole SF, Dinarello CA. Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. Cytokine 1989;1:14-22.
48. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J. Clin. Invest. 1989;84:2008-2011.
49. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br. J. Haematol. 1999;104:350-357.
50. Hassan G, Moreno S, Massimi M, Di Biagio P, Stefanini S. Interleukin-1-producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis. J. Hepatol. 1997;27:6-17.
51. Ghezzi P, Dinarello CA. IL-1 induces IL-1. III. Specific inhibition of IL-I production by IFN-gamma. J. Immunol. 1988;140:4238-4244.
52. Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol. 1990;144:2216-2222.
53. Lust JA, Lacy MQ, Dispenzieri A, Gertz MA, Zeldenrust SR, Greipp PR, Witzig TE, Hoering A, Moon-Tasson LL, Timm MM, Rajkumar SV, Donovan KA. Interleukin-1 receptor antagonist (IL-1Ra) targets the proliferative component in early stage myeloma. Blood 2004;104:2412.
54. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991;77:587-593.
55. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-1204.